Beijing Cancer Hospital
Peking University Cancer Hospital: China's National Team in Cancer Prevention and Control and an International Benchmark
I. Hospital Overview
Founded in 1976, Peking University Cancer Hospital is a Grade A tertiary specialized cancer hospital integrating medical treatment, teaching, research, and prevention. Affiliated with Peking University Health Science Center, it serves as a partner institution of the National Cancer Center, a national key discipline unit in oncology, and a national clinical trial institution for anticancer drugs. It also functions as the supporting unit for the Beijing Cancer Institute. The hospital operates across two campuses (main campus at 52 Fucheng Road, Haidian District; Zhongguancun campus at Xierqi Street, Haidian District), with over 2,600 beds. It handles more than 1.1 million outpatient visits annually and performs over 15,000 surgical procedures annually. Its services extend to all 31 provinces and municipalities in China and over 50 countries worldwide, establishing it as China's “national team” in cancer prevention and treatment and a vital international exchange platform in oncology.
II. Technological Advantages
As a pioneer in China's cancer diagnosis and treatment, Peking University Cancer Hospital centers its approach on “precision medicine,” developing six core technological strengths across the entire cancer prevention and control cycle:
• Multidisciplinary Team (MDT) Approach: Among China's earliest adopters of MDT for cancer care, covering over 20 cancer types, including gastric, colorectal, breast, and lymphoma. Conducts over 30,000 MDT consultations annually with over 95% treatment plan compliance, achieving patient 5-year survival rates significantly higher than industry averages.
• Precision Therapy and Translational Medicine: Leveraging the National Key Laboratory of Tumor Genomics, the hospital conducts driver gene testing (e.g., EGFR/ALK for lung cancer, RAS/BRAF for colorectal cancer) and liquid biopsy (circulating tumor DNA) to guide targeted and immunotherapy. It also accelerates “lab-to-clinical” translation, having led or participated in over 200 international multicenter clinical trials for new drugs in the past five years.
• Minimally Invasive and Robotic Surgery: Comprehensive application of the Da Vinci Surgical System (Xi) across thoracic, gastrointestinal, and hepatobiliary-pancreatic surgery, performing over 800 robotic procedures annually. Mature techniques include laparoscopic radical gastrectomy/colorectal resection and radiofrequency ablation for hepatocellular carcinoma, offering minimal trauma and rapid recovery.
• Precision Radiotherapy: Equipped with world-leading radiotherapy systems (e.g., Varian TrueBeam linear accelerator, TOMO spiral tomotherapy), supporting image-guided radiotherapy (IGRT) and adaptive radiotherapy (ART). Delivers curative radiotherapy for early-stage lung and prostate cancers, while implementing precision palliative radiotherapy for advanced tumors.
• Early Cancer Screening and Prevention: A three-tiered screening system targeting “high-risk populations → precancerous lesions → early-stage cancers” has been established. Early screening programs for gastric cancer (gastroscopy + serology), colorectal cancer (colonoscopy + fecal DNA), and breast cancer (mammography + ultrasound) are conducted, achieving a 40% higher early-stage cancer detection rate compared to conventional screening.
• Smart Healthcare Empowerment: Establishing an “online cancer hospital” supporting virtual consultations, test scheduling, and report interpretation; introducing AI-assisted diagnosis systems (e.g., lung nodule benign/malignant differentiation, automated pathology slide analysis) to reduce diagnostic time by over 30%.
• Smart Healthcare Empowerment: Established an “online cancer hospital” supporting virtual consultations, test scheduling, and report interpretation; introduced AI-assisted diagnosis systems (e.g., distinguishing benign/malignant lung nodules, intelligent pathology slide analysis), reducing diagnosis time by over 30%.
III. Hospital's Leading Specialties
The hospital boasts multiple nationally recognized key specialties, consistently ranking among the top institutions in China's oncology field:
• National Key Clinical Specialties (Oncology):
• Gastric Cancer Surgery (pioneered standard radical gastrectomy in China, achieving over 65% five-year survival rate);
• Colorectal Surgery (Nationwide leader in laparoscopic colorectal cancer radical resection cases; 90% sphincter preservation rate for ultra-low rectal cancer);
• Medical Breast Cancer (Targeted and endocrine therapy regimens based on the latest international guidelines; doubled progression-free survival in advanced breast cancer);
• Lymphoma Department (Diagnostic accuracy exceeding 90% for complex lymphomas; CAR-T cell therapy efficacy exceeding 70% for refractory lymphomas).
• Key Specialties Supported by the National Cancer Center:
• Hepatocellular Carcinoma Surgery (combined with liver transplantation for advanced liver cancer, achieving 5-year survival rates exceeding 50%);
• Pancreatic Surgery (pancreatoduodenectomy mortality rate <1%, robotic-assisted surgeries account for over 60%);
• Thoracic Oncology (precision treatment for non-small cell lung cancer; leading institution for clinical research on immunotherapy for small cell lung cancer).
• Beijing Key Specialties:
• Pediatric Oncology (Comprehensive treatment for childhood malignancies including neuroblastoma and Wilms tumor);
• Radiation Oncology (Precision radiotherapy for head and neck tumors, prostate cancer);
• Interventional Radiology (tumor radiofrequency/microwave ablation, arterial chemoembolization).
IV. Hospital Department Structure
The hospital's department structure focuses on the entire cancer prevention and treatment chain, covering prevention, diagnosis, treatment, rehabilitation, and research:
• Clinical Departments:
• Surgical Oncology: Gastric Cancer Surgery, Colorectal Surgery, Breast Cancer Surgery, Hepatobiliary Pancreatic Surgery, Thoracic Surgery, Head and Neck Surgery, Neuro-Oncology Surgery, Bone and Soft Tissue Tumor Surgery, Pediatric Oncology Surgery.
• Medical Oncology: Gastric Cancer Medicine, Colorectal Medicine, Breast Cancer Medicine, Lymphoma Medicine, Thoracic Oncology Medicine, Abdominal Oncology Medicine, Pediatric Oncology Medicine.
• Radiation Oncology: Head and Neck Radiation Therapy, Thoracic Radiation Therapy, Abdominal and Pelvic Radiation Therapy, Breast Radiation Therapy, Pediatric Oncology Radiation Therapy.
• Other Core Departments: Anesthesiology, Critical Care Medicine (ICU), Pathology, Radiology, Nuclear Medicine (PET-CT/PET-MR), Laboratory Medicine (ISO 15189 Certified), Interventional Radiology, Rehabilitation Medicine.
• Medical Technology & Support Departments:
• Central Laboratory (Genomics, Proteomics Research), Biobank (Archiving Over 500,000 Tumor Tissue Samples), Clinical Trials Center (Phase I-IV Drug Trials).
• International Medical Department (Dedicated Wards, Providing High-End Oncology Services), Palliative Care Center (Comfort Care for Advanced Cancer).
• Specialized Centers:
• Multidisciplinary Oncology Center (MDT);
• Cancer Early Screening and Prevention Center;
• Cancer Rehabilitation and Supportive Care Center (Nutrition, Psychology, Pain Management);
• Cancer Biotherapy Center (Immunotherapies including CAR-T, PD-1 Inhibitors).
V. Medical Devices and Equipment
The hospital is equipped with world-class oncology diagnostic and therapeutic devices, enabling precise diagnosis and cutting-edge treatment:
• Diagnostic Equipment:
• 5.0T Magnetic Resonance Imaging (MRI, for precise neuro-oncology imaging);
• 256-slice spiral CT (for low-dose lung cancer screening);
• PET-MR (whole-body tumor early screening and precise localization);
• Digital Mammography (Mammography + Tomosynthesis, early breast cancer diagnosis);
• Gene Sequencer (Illumina NovaSeq 6000, whole-exome sequencing for tumors).
• Therapeutic Equipment:
• Fourth-generation Da Vinci surgical robot (Xi, for thoracic/gastrointestinal/hepatobiliary surgery);
• Varian TrueBeam linear accelerator (supports IGRT/ART, radiotherapy for head and neck/lung tumors);
• TOMO spiral tomotherapy system (multi-field irradiation for complex tumors);
• Radiofrequency Ablation System (minimally invasive treatment for liver/lung cancer);
• Cryoablation System (focal therapy for prostate/kidney cancer).
• Support Equipment:
• Fully Automated Slide Scanning System (digital pathology AI analysis);
• High-throughput gene sequencing platform (tumor mutational burden detection);
• GMP-certified cell therapy laboratory (CAR-T cell preparation).
VI. International Patient Services
As a National Health Commission-designated “Designated Hospital for Foreign Medical Services,” Peking University Cancer Hospital provides international patients with comprehensive, high-end, professional, and humanistic services throughout their treatment journey:
• Multilingual medical support: Professional interpreters fluent in English, Japanese, Korean, Spanish, and Arabic. Physicians in key departments (surgery, internal medicine, radiation oncology) hold international oncology certifications (e.g., ESMO membership).
• Dedicated International Care Pathway: The Independent International Medical Center (IMC) facilitates appointment scheduling, priority testing, and expedited multidisciplinary team (MDT) consultations. Patient rooms are single/double occupancy with international-standard bedding, private bathrooms, and religious accommodation facilities (e.g., prayer rooms, vegetarian kitchens).
• Insurance & Payment Convenience: Supports direct billing with overseas health insurers (MSH, Cigna, Allianz, BUPA, etc.), provides bilingual cost breakdowns and medical record translations, and assists with visa extensions and flight rebooking.
• Comprehensive Patient Care: Assigns dedicated international medical coordinators from initial assessment through follow-up recovery; hosts regular “International Patient Exchange Meetings” to share treatment experiences and offer psychological support.
VII. International Patient Testimonials
• David (Stomach Cancer, USA): “At the MDT meeting, I met top specialists from surgery, internal medicine, and radiation oncology. They clearly explained the combined treatment plan of surgery + chemotherapy + immunotherapy in English. The Da Vinci robotic surgery left almost no scars, and my recovery was much faster than expected!”
• Yuki (Breast Cancer, Japan): " Professor Watanabe from Breast Cancer Internal Medicine adjusted my targeted therapy based on my genetic test results. My tumor markers are now within normal range. Nurses from the International Medical Department follow up weekly via video call on my recovery—truly thoughtful."
• Ahmed (Arabic patient, lymphoma): "During CAR-T cell therapy, doctors monitored my cytokine levels daily and promptly managed side effects like fever. The hospital environment is quiet and clean, and even the indicator lights on examination equipment are multilingual—it feels completely familiar."
VIII. Hospital Contact Information
• Switchboard: 010-88121122 (Main Campus), 010-62965600 (Zhongguancun Campus)
• International Medical Department: 010-88121155 (Appointments), 010-88121166 (Inquiries)
• WeChat Official Account: “Peking University Cancer Hospital Service Account” (Supports appointment booking, report inquiries, clinical trial recruitment)
IX. Address and Transportation Routes
• Main Campus Address: No. 52 Fucheng Road, Haidian District, Beijing (near Aerospace Bridge and Dinghui Temple commercial districts).
• Zhongguancun Campus Address: No. 28A Xierqi Street, Haidian District, Beijing (near Zhongguancun Software Park).
Transportation Guide:
• Main Campus:
• Subway: Exit D from Cishou Temple Station (Line 10), walk approximately 800 meters; Exit B from Huayuanqiao Station (Line 6), walk approximately 1 kilometer.
• Bus: “Beijing Cancer Hospital” stop (Routes 335, 336, 746); “Dinghui Temple East” stop (Routes 56, 121, 336).
• Driving: Hospital underground parking available (rate: ¥8/hour, daily cap ¥80); nearby public parking at Hangtianqiao.
• Zhongguancun Campus:
• Subway: Exit A at Xierqi Station (Line 13), walk approximately 1.2 km; Transfer to Bus Special Line 123 at Changping Line's “Qinghe Station” to “Xierqi Dajie Station”.
• Bus: “Xierqi Dajie Station” (Special Line 123, Route 543, Route 560); “Shangdi Qijie Xikou Station” (Route 333, Route 963).
• By Car: On-site surface parking available (rate: ¥6/hour, daily cap ¥60). Underground parking at the nearby Software Park.
Peking University Cancer Hospital, guided by its mission to “Conquer Cancer, Guard Life,” continues to lead innovation and advancement in China's cancer prevention and treatment. We are dedicated to providing domestic and international patients with medical services that are “more precise, more compassionate, and more hopeful.”
Document dated 2025-09-15 14:31 Modify